HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakagawa, S. H. Articles by Tager, H. S. Search for Related Content PubMed PubMed Citation Articles by Nakagawa, S. H. Articles by Tager, H. S. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 261, Issue 16, 7332-7341, 06, 1986

Role of the phenylalanine B25 side chain in directing insulin interaction with its receptor. Steric and conformational effects

SH Nakagawa and HS Tager

To gain an understanding of the causes of decreased biological activity in insulins bearing amino acid substitutions at position B25 and the importance of the PheB25 side chain in directing hormone-receptor interactions, we have prepared a variety of insulin analogs and have studied both their interactions with isolated canine hepatocytes and their abilities to stimulate glucose oxidation by isolated rat adipocytes. The semisynthetic analogs fall into three structural classes: (a) analogs in which the COOH-terminal 5, 6, or 7 residues of the insulin B-chain have been deleted, but in which the COOH-terminal residue of the B-chain has been derivatized by alpha-carboxamidation; (b) analogs in which PheB25 has been replaced by unnatural aromatic or natural L-amino acids; and (c) analogs in which the COOH-terminal 5 residues of the insulin B-chain have been deleted and in which residue B25 has been replaced by selected alpha-carboxamidated amino acids. Our results showed that (a) insulin residues B26-B30 can be deleted without decrease in biological potency, whereas deletion of residues B25-B30 and B24-B30 causes a marked and cumulative decrease in potency; (b) replacement of PheB25 in insulin by Leu or Ser results in analogs with biological potency even less than that observed when residues B25-B30 are deleted; (c) the side chain bulk of naphthyl(1)-alanine or naphthyl(2)-alanine at position B25 is well tolerated during insulin interactions with receptor, whereas that of homophenylalanine is not; and (d) the decreased biological potency attending substitution of insulin PheB25 by Ala, Ser, Leu, or homophenylalanine is reversed, in part or in total, by deletion of COOH-terminal residues B26-B30. Additional experiments showed that the rate of dissociation of receptor- bound 125I-labeled insulin from isolated hepatocytes is enhanced by incubating cells with insulin or [naphthyl(2)-alanineB25]insulin, but not with analogs in which PheB25 is replaced by serine, leucine, or homophenylalanine; deletion of residues B26-B30, however, results in analogs that enhance the rate of dissociation of receptor-bound insulin in all cases studied. We conclude that (a) steric hindrance involving the COOH-terminal domain of the B chain plays a major role in directing the interaction of insulin with its receptor; (b) the initial negative effect of this domain is reversed upon the filling of a site reflecting interaction of the receptor and the beta-aromatic ring of the PheB25 side chain.(ABSTRACT TRUNCATED AT 400 WORDS)
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Q.-x. Hua, S. H. Nakagawa, W. Jia, K. Huang, N. B. Phillips, S.-q. Hu, and M. A. Weiss Design of an Active Ultrastable Single-chain Insulin Analog: SYNTHESIS, STRUCTURE, AND THERAPEUTIC IMPLICATIONS J. Biol. Chem., May 23, 2008; 283(21): 14703 - 14716. [Abstract] [Full Text] [PDF]

				Q.-x. Hua, M. Liu, S.-Q. Hu, W. Jia, P. Arvan, and M. A. Weiss A Conserved Histidine in Insulin Is Required for the Foldability of Human Proinsulin: STRUCTURE AND FUNCTION OF AN ALAB5 ANALOG J. Biol. Chem., August 25, 2006; 281(34): 24889 - 24899. [Abstract] [Full Text] [PDF]

				B. Xu, S.-Q. Hu, Y.-C. Chu, S. Wang, R.-y. Wang, S. H. Nakagawa, P. G. Katsoyannis, and M. A. Weiss Diabetes-Associated Mutations in Insulin Identify Invariant Receptor Contacts Diabetes, June 1, 2004; 53(6): 1599 - 1602. [Abstract] [Full Text] [PDF]

				C. C. Yip and P. Ottensmeyer Three-dimensional Structural Interactions of Insulin and Its Receptor J. Biol. Chem., July 18, 2003; 278(30): 27329 - 27332. [Full Text] [PDF]

				F. Authier, G. M. Danielsen, M. Kouach, G. Briand, and G. Chauvet Identification of Insulin Domains Important for Binding to and Degradation by Endosomal Acidic Insulinase Endocrinology, January 1, 2001; 142(1): 276 - 289. [Abstract] [Full Text] [PDF]

				D. C. Mynarcik, P. F. Williams, L. Schaffer, G. Q. Yu, and J. Whittaker Identification of Common Ligand Binding Determinants of the Insulin and Insulin-like Growth Factor 1 Receptors. INSIGHTS INTO MECHANISMS OF LIGAND BINDING J. Biol. Chem., July 25, 1997; 272(30): 18650 - 18655. [Abstract] [Full Text] [PDF]

				S.-j. Bao, D.-l. Xie, J.-p. Zhang, W.-r. Chang, and D.-c. Liang Crystal structure of desheptapeptide(B24-B30)insulin at 1.6 A resolution: Implications for receptor binding PNAS, April 1, 1997; 94(7): 2975 - 2980. [Abstract] [Full Text] [PDF]

				D. C. Mynarcik, P. F. Williams, L. Schaffer, G. Q. Yu, and J. Whittaker Analog Binding Properties of Insulin Receptor Mutants. IDENTIFICATION OF AMINO ACIDS INTERACTING WITH THE COOH TERMINUS OF THE B-CHAIN OF THE INSULIN MOLECULE J. Biol. Chem., January 24, 1997; 272(4): 2077 - 2081. [Abstract] [Full Text] [PDF]